A Phase 3 interventional study of Lamictal in Epilepsy, sponsored by GlaxoSmithKline. Completed at 13 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-10-20.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing lamotrigine in Epilepsy — 2 open to participants now, 2 under way, none of them phase 3. Lamotrigine · Epilepsy.
Among the 36 studies testing lamotrigine in Epilepsy, this one is the 20th largest by enrollment, is one of 3 that started in 2011, is one of 12 in phase 3, and was the 24th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 36 studies testing lamotrigine in Epilepsy are open now. Recruiting first, the newest first:
Assiut University
Ages 2–12 · Healthy volunteers
National Taiwan University Hospital
Ages 20+
Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 76 across the 36 interventional studies. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
54 studies in Epilepsy by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 53 finished, 23 (43%) have results posted.
Among the 54 studies in Epilepsy by GlaxoSmithKline, this one is the 22nd largest by enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2011, is one of 18 in phase 3, and was the 33rd registered.
GlaxoSmithKline’s Epilepsy studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing lamotrigine in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 54 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, uncontrolled, open-label study conducted in Japan and South Korea to evaluate the efficacy and safety of lamotrigine monotherapy in subjects with newly diagnosed epilepsy and those with recurrent epilepsy (currently untreated).
The study is composed of baseline, escalation phase, maintenance phase, taper phase and post study examination. During the escalation phase, the investigational product is administered orally at 25 mg/day for 2 weeks, then 50 mg/day for 2 weeks and finally 100 mg/day for 2 weeks. During the maintenance phase, 200 mg/day is administered orally for 24 weeks. However, the dose can be decreased to 100 mg/day if there are safety concerns. Also, if it is confirmed that the seizures cannot be controlled at the dose of 200 mg/day, the dose can be gradually increased up to 400 mg/day by 50-100 mg/day at intervals of at least 1 week. As a rule, lamotrigine should be administered once daily (in the evening), but the dose exceeding 200 mg/day can be administered in two divided doses (in the morning and evening). After the completion of maintenance phase, Japanese subjects who have responded to lamotrigine without tolerability issues are eligible to enter an extension phase of the study if indicated, until either approval of this indication (monotherapy in epilepsy) or after 24 months after LSLV (Last Subject's Last Visit) of the maintenance phase, whichever is sooner.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Target disease: Subjects with newly diagnosed epilepsy or recurrent epilepsy which is untreated, having the following seizure types as classified by the International Classification of Seizures.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No comparison.
Drug: Lamictal
No comparison.
Number of Participants Who Were Seizure Free in the Maintenance Phase (Across Seizure Types and by Seizure Type Within 6 Months Prior to the Start of the Study)
Participants were considered to be seizure free if they did not report any seizures during the Maintenance Phase. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.
Time frame: Weeks 7 to 30
Time to Withdrawal/Dropout From the Study (Across Seizure Types and by Seizure Type in Past 6 Months in the Escalation and Maintenance Phases)
Time to withdrawal is defined as the time from the start of treatment until withdrawal from the study. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures which affect only a small region of the brain, often the temporal lobes or hippocampi. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.
Time frame: up to Week 30
Time to the First Seizure in the Maintenance Phase (Across Seizure Types and by Seizure Type)
The time to the first seizure in the Maintenance Phase is measured at the time the first seizure occurred in the Maintenance Phase. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.
Time frame: Weeks 7 to 30
A total of 70 participants were enrolled; 3 participants were screened but withdrew from the study before prescription of the first investigational product (67), and only 65 of the participants received at least one dose of the investigational product which comprised the safety population.
| Milestone | Lamotrigine |
|---|---|
| Started | 67 |
| Begin escalation phase (ep; 6 weeks) | 67 |
| Received treatment | 65 |
| Complete ep (6 weeks) | 52 |
| Begin maintenance phase (mp; 24 weeks) | 52 |
| Complete mp (24 weeks) | 42 |
| Begin extension phase (exp; gt= 24weeks) | 19 |
| Complete exp (gt= 24 weeks) | 19 |
| Completed | 32 |
| Not completed | 35 |
| Withdrew: Adverse event | 18 |
| Withdrew: Lack of efficacy | 7 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Protocol-defined stopping criteria | 2 |
| Withdrew: Physician decision | 4 |
| Withdrew: Withdrawal by subject | 3 |
Participants were considered to be seizure free if they did not report any seizures during the Maintenance Phase. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.
| participants | Lamotrigine |
|---|---|
| All, n=65 | 28 |
| A+B+C, n=55 | 22 |
| A+B, n=42 | 17 |
| C, n=33 | 23 |
| D5, n=10 | 8 |
Time to withdrawal is defined as the time from the start of treatment until withdrawal from the study. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures which affect only a small region of the brain, often the temporal lobes or hippocampi. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.
| Days | Lamotrigine |
|---|---|
| All, n=65 | 150.0 ± 8.99 |
| A+B+C, n=55 | 148.4 ± 9.72 |
| A+B, n=42 | 147.9 ± 10.72 |
| C, n=33 | 168.0 ± 10.91 |
| D5, n=10 | 14.6 ± 0.54 |
The time to the first seizure in the Maintenance Phase is measured at the time the first seizure occurred in the Maintenance Phase. Seizure types are defined as: ALL=any type of seizure; A: simple partial seizures, B: complex partial seizures; C: partial seizures evolving to secondary generation seizures; D5: tonic-clonic seizures. Simple partial seizures are seizures that affect only a small region of the brain, often the temporal lobes or hippocampi. Complex partial seizures are epileptic seizures that are associated with bilateral cerebral hemisphere involvement and cause impairment of awareness or responsiveness. Partial seizures evolving to secondary generation seizures are seizures that start as partial seizures, then spread to include the entire brain. Tonic-clonic seizures are a type of generalized seizure that affects the entire brain.
| Days | Lamotrigine |
|---|---|
| All, n=52 | 103.0 ± 9.43 |
| A+B+C, n=44 | 100.4 ± 10.44 |
| A+B, n=34 | 94.2 ± 12.22 |
| C, n=29 | 113.3 ± 12.06 |
| D5, n=8 | NA ± NA |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from study medication start until the end of treatment (up to Week 54).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lamotrigine | — | 8/65 (12.3%) | 38/65 (58.5%) |
| Event | Lamotrigine |
|---|---|
| EpilepsyNervous system disorders | 2/65 |
| HaemorrhoidsGastrointestinal disorders | 1/65 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/65 |
| Intestinal obstructionGastrointestinal disorders | 1/65 |
| Sick sinus syndromeCardiac disorders | 1/65 |
| Electrocardiogram QT prolongedInvestigations | 1/65 |
| Decreased appetiteMetabolism and nutrition disorders | 1/65 |
| Stevens-Johnson syndromeSkin and subcutaneous tissue disorders | 1/65 |
| Pulmonary contusionInjury, poisoning and procedural complications | 1/65 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/65 |
| Event | Lamotrigine |
|---|---|
| NasopharyngitisInfections and infestations | 15/65 |
| HeadacheNervous system disorders | 14/65 |
| RashSkin and subcutaneous tissue disorders | 8/65 |
| NauseaGastrointestinal disorders | 6/65 |
| DizzinessNervous system disorders | 4/65 |
| Drug eruptionSkin and subcutaneous tissue disorders | 4/65 |
| Abdominal pain upperGastrointestinal disorders | 4/65 |
| InsomniaPsychiatric disorders | 4/65 |
Baseline data were collected in members of the Safety Population, comprised of all participants who had taken at least one dose of investigational product.
| Age, Continuous(Years) | Lamotrigine |
|---|---|
| Mean | 37.3 ± 20.20 |
| Sex: Female, Male(Participants) | Lamotrigine |
|---|---|
| Female | 26 |
| Male | 39 |
| Race/Ethnicity, Customized(participants) | Lamotrigine |
|---|---|
| Asian - East Asian Heritage | 26 |
| Asian - Japanese Heritage | 39 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Sep 2011, a primary completion of Mar 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine